JOHNSON & JOHNSON
About JOHNSON & JOHNSON
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
American Credentials
Each credential is independently reviewed before it’s awarded · last reviewed Jun 9, 2026. How this is verified →
Financial summary
- Revenue FY2025
- $94.2B
- Net income
- $26.8B
- Total assets
- $199.2B
- Market cap
- $560.3B
- Gross margin
- 67.9%
- Operating margin
- 34.6%
- Net margin
- 28.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $94.2B
- Cost of revenue
- $30.3B
- Gross profit
- $63.9B
- Operating expenses
- $31.4B
- Operating income
- $32.6B
- Income tax
- $5.8B
- Net income
- $26.8B
- EPS (basic)
- $11.13
- EPS (diluted)
- $11.03
Balance sheet
- Total assets
- $199.2B
- Current assets
- $55.6B
- Total liabilities
- $117.7B
- Current liabilities
- $54.1B
- Shareholders’ equity
- $81.5B
Cash flow
- Operating cash flow
- $24.5B
- Investing cash flow
- -$23.6B
- Financing cash flow
- -$5.5B
- Net cash flow
- -$4.4B
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $560.3B
- P/E ratio
- 21.0
- EPS (diluted)
- $11.03
- Dividend yield
- 2.31%
- Shares outstanding
- 2.4B
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 25, 1944
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $26.8B in FY2025.
- Revenue grew 14% from FY2020 to FY2025.
- Gross margin of 67.9%, net margin 28.5%.
- Trading 7% below its 52-week high.
- Pays a dividend yielding about 2.31% annually.
- Valued at a price-to-earnings (P/E) ratio of 21.0.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
Peers & competitors
No reviews yet. Be the first to review JOHNSON & JOHNSON.
Write a review
News about JOHNSON & JOHNSON
News & sentiment via Polygon.io
